Showing results (481-490 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|February 6, 2022
The risk of mental illness in people living with HIV in the UK: a propensity score-matched cohort studyTiffany E Gooden, Mike Gardner, Jingya Wang, et al.
The Lancet. HIV|April 23, 2022
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trialNicholas I Paton, Joseph Musaazi, Cissy Kityo, et al.
The Lancet. HIV|March 19, 2022
Tailoring care for frail and lonely older people with HIV in Canada: a cross-sectional studyJacqueline McMillan, Farwa Naqvi, John Gill
The Lancet. HIV|June 17, 2019
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trialWillem D F Venter, Michelle Moorhouse, Simiso Sokhela, et al.
The Lancet. HIV|October 17, 2021
Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuityAaloke Mody, Izukanji Sikazwe, Angella Sandra Namwase, et al.
The Lancet. HIV|July 10, 2019
Use of electronic health record data and machine learning to identify candidates for HIV pre-exposure prophylaxis: a modelling studyJulia L Marcus, Leo B Hurley, Douglas S Krakower, et al.
The Lancet. HIV|October 19, 2019
HIV controllers: to treat or not to treat? Is that the right question?Nicolas Noël, Asier Saez-Cirion, Véronique Avettand-Fenoël, et al.
The Lancet. HIV|October 12, 2019
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort studySerge P Eholie, Raoul Moh, Aïda Benalycherif, et al.
The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.
The Lancet. HIV|May 13, 2019
Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trialsHolly Janes, Deborah Donnell, Peter B Gilbert, et al.
Pageof 79